Details of the Drug

General Information of Drug (ID: DMPENAL)

Drug Name

FSI-189

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inhibitory receptor SHPS-1 (SIRPA)	TTBRJS9	SHPS1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04502706) Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
2	T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391.